Persistent effect of in utero meso-2,3-dimercaptosuccinic acid (DMSA) on immune function and lead-induced immunotoxicity

Toxicology

Volumn 132, Issue 1, 1999, Pages 67-79

  Chen, Suping ^a   Golemboski, Karen A ^a   Sanders, Forrest S ^a   Dietert, Rodney R ^a  

^a Dept Microbiol Immunol Coll V   (United States)

Author keywords

Immunotoxicity; Lead acetate; Meso 2,3 dimercaptosuccinic acid (DMSA)

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 4; LEAD; SUCCIMER; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHELATION THERAPY; FEMALE; IMMUNE FUNCTION TEST; IMMUNOTOXICITY; INTRAGASTRIC DRUG ADMINISTRATION; MOUSE; NONHUMAN; PREGNANCY; PRIORITY JOURNAL;

ANIMALS; ANTIDOTES; CELLS, CULTURED; CHELATING AGENTS; CYTOKINES; EMBRYONIC AND FETAL DEVELOPMENT; FEMALE; HYPERSENSITIVITY, DELAYED; IMMUNE SYSTEM; LACTATION; LEAD; MACROPHAGES; MALE; MILK; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RATS; RATS, INBRED F344; SPLEEN; SUCCIMER;

EID: 0032894142     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-483X(98)00139-5     Document Type: Article

References (52)

1. Aposhian H.V., Majorino R.M., Rivera M., Bruce D.C., Dart R.C., Hurlbert K.M., Levine D.J., Zheng W., Fernando Q., Carter D. Human studies with the chelating agents; DMPS and DMSA. J. Tox. Clin. Toxicol. 30:1992;505-528.
2. Bell R.C., Golemboski K.A., Dietert R.R., Campbell T.C. Long-term intake of a low-casein diet is associated with higher relative NK cell cytotoxic activity in F344 Rats. Nutr. Cancer. 22:1994;151-162.
3. Chandra R.K. Nutrition and immunoregulation; significance for host resistance to tumors and infectious diseases in humans and rodents. J. Nutr. 122:1992;754-757.
4. Chen S., Miller T.E., Golemboski K.A., Dietert R.R. Suppression of macrophage metabolite production by lead glutamate in vitro is reversed by meso-2,3-dimercaptosuccinic acid (DMSA). In vitro Toxicol. 10:1997;351-358.
5. Chisolm J.J. Jr. BAL; EDTA; DMSA and DMPS in the treatment of lead poisoning in children. J. Tox. Clin. Toxicol. 30:1992;493-504.
6. Clerici M., Hakim F.T., Venzon D.J., Blatt S., Hendrix C.W., Wynn T.A., Shearer G.M. Changes in interleukin-2 and interleukin-4 production in asymptomatic human immunodeficiency virus-seropositive individuals. J. Clin. Invest. 91:1993;759-765.
7. + T cell subsets in vivo. Immunol. Rev. 123:1991;189-207.
8. Cory-Slechta D.A. Mobilization and redistribution of lead over the course of DMSA chelation therapy and long term efficacy. J. Pharmacol. Exp. Ther. 246:1988;84-91.
9. Exon, J.H., Talcott, P.A., 1995. Enzyme-linked immunosorbent assay (ELISA) for detection of specific IgG antibody in rats. In: Methods in Immunology, vol. 1. Wiley-Liss, pp. 109-124.
10. Exon J.H., Bussiere J.L., Mather G.G. Immunotoxicity testing in the rat: an improved multiple assay model. Int. J. Immunopharmacol. 12:1990;699-701.
11. Ewers U., Stiller-Winkler R., Idel H. Serum immunoglobulin, complement C3, and salivary IgA levels in lead workers. Environ. Res. 29:1982;351-357.
12. Faith R.E., Luster M.I., Kimmel C.A. Effects of combined pre- and postnatal lead exposure on cell mediated immune functions. Clin. Exp. Immunol. 35:1979;413-420.
13. Flora S.J.S., Kumar P. Biochemical and immunotoxicological alterations following repeated gallium arsenide exposure and their recoveries by meso-2,3-dimercaptosuccinic acid and 2,3-dimercaptopropane 1-sulfonate administration in rats. Environ. Toxicol. Pharmacol. 2:1996;315-320.
14. Flora S.J.S., Tandon S. K. Beneficial effects of zinc supplementation during chelation treatment of lead intoxication in rats. Toxicology. 64:1990;129-139.
15. Flora S.J.S. Influence of simultaneous supplementation of zinc and copper during chelation of lead in rats. Hum. Exp. Toxicol. 10:1991;331-336.
16. Friedheim E., Graziano J.H., Popovac D., Dragovic D., Kaul B. Treatment of lead poisoning by 2,3-dimercaptosuccinic acid. Lancet. 2:1978;1234-1236.
17. Gainer J.H. Lead aggravates viral disease and represses the antiviral activity of interferon inducers. Environ. Health. Perspect. 7:1974;113-119.
18. Goyer R.A. Lead toxicology: current concerns. Environ. Health. Perspect. 100:1993;177-187.
19. Graziano J.H. Role of 2,3-dimercaptosuccinic acid in the treatment of heavy metal poisoning. Med. Toxicol. 1:1986;155-162.
20. Graziano J.H., Siris E., Lolacono N., Silverberg S. J., Turgeon L. 2,3-dimercaptosuccinic acid as an antidote for lead intoxication. Clin. Pharmacol. Ther. 37:1985;431-438.
21. Graziano J.H., Lolacono N.J., Meyer P. Dose-response study of oral 2,3-dimercaptosuccinic acid in children with elevated blood lead concentrations. J. Pediatr. 113:1988;751-757.
22. 15N] nitrite in biological fluids. Anal. Biochem. 126:1982;131-138.
23. Haust H.L., Poon H.C., Inwood M., Ohea E.K., Haines D.S., Forrest C.J., Keys D.S. Occupational lead exposure: studies in two brothers showing differential susceptibility to lead. Clin. Biochem. 18:1985;102-108.
24. Heinzel F.P., Sadick M.D., Holaday B.J., Coffman R.L., Locksley R.M. Reciprocal expression of interferon γ or interleukin 4 during the resolution or progression of murine leishmaniasis. J. Exp. Med. 169:1989;59-72.
25. Heo Y., Parsons P.J., Lawrence D.A. Lead differentially modifies cytokine production in vitro and in vivo. Toxicol. Appl. Pharmacol. 138:1996;149-157.
26. Horiguchi S., Endo G., Kiyota I., Teromoto K., Shinagawa K., Wakitani F., Tanaka H., Konishi Y., Ota A. Frequency of cold infections in workers at a lead refinery. Osaka City Med. J. 38:1992;79-81.
27. Hu H., Moller G., Abedi-Valugerdi M. Thiol compounds inhibit mercury-induced immunological and immuopathological alterations in susceptible mice. Clin. Exp. Immunol. 107:1997;68-75.
28. Kowolenko M., Tracy L., Lawrence D.A. Early effects of lead on bone marrow cell responsiveness in mice challenged with Listeria monocytogenes. Fundam. Appl. Toxicol. 17:1991;75-82.
29. Kurt-Jones E.A., Hamberg S., Ohara J., Paul W.E., Abbas K. Heterogeneity of helper/inducer T lymphocytes I lymphokine production and lymphokine responsiveness. J. Exp. Med. 166:1987;1774-1787.
30. Lawrence D.A. In vivo and in vitro effects of lead on humoral and cell-mediated immunity. Infect. Immun. 31:1981;136-143.
31. Lewis R.E., Buchsbaum M., Whitaker D., Murphy G.F. Intercellular adhesion molecule expression in the evolving human cutaneous delayed hypersensitivity reaction. J. Invest. Dermatol. 93:1989;672-677.
32. Luster M.I., Faith R.E., Kimmel C.A. Depression of humoral immunity in rats following chronic developmental lead exposure. J. Environ. Pathol. Toxicol. 1:1978;397-402.
33. + T cell subsets. Toxicol. Appl. Pharmacol. 111:1991;13-23.
34. Miller T.E., Golemboski K.A., Ha R.S., Bunn T., Sanders F.S., Dietert R.R. Developmental exposure to lead causes persistent immunotoxicity in Fischer 344 rats. Toxicol. Sci. 42:1998;129-135.
35. Neilan B.A., Faddeini L., Mcjilton C.E., Handwerger B.S. Decreased T cell function in mice exposed to chronic low levels of lead. Clin. Exp. Immunol. 39:1980;746-749.
36. Nelson W.L., Kaye A., Moore M., Williams H.H., Herrington B.L. Milking techniques and the composition of guinea pig milk. J. Nutr. 44:1951;585-594.
37. Palminger H.I., Jorhem L., Oskarsson A. Placental and lactational transfer of lead in rats: a study on the lactational process and effects on offspring. Arch. Toxicol. 69:1995;596-602.
38. Pappas J.B., Ahlquist J.T., Allen E.M., Banner W. Jr. Oral dimercaptosuccinic acid and ongoing exposure to lead: effects on heme synthesis and lead distribution in a rat model. Toxicol. Appl. Pharmacol. 133:1995;121-129.
39. Paternain J.L., Ortega A., Domingo J.L., Llobet J.M. Oral meso-2,3-dimercaptosuccinic acid in pregnant Sprague-Dawley rats: teratogenicity and alterations in mineral metabolism II effect on mineral metabolism. J. Toxicol. Environ. Health. 30:1990;191-197.
40. Pruszkowska E., Carnick G.R., Slavin W. Blood lead determination with the platform furnace technique. Atom. Spect. 4:1983;59-61.
41. Rand M.L., Warren J.S., Mansour M.K., Newman W., Ringler D.J. Inhibition of T cell recruitment and cutaneous delayed-type hypersensitivity-induced inflammation with antibodies to monocyte chemoattractant protein-1. Am. J. Pathol. 148:1996;855-864.
42. Redig P.T., Lawler E.M., Schwartz S., Dunnette J.L., Stephenson B., Duke G.E. Effect of chronic exposure to sublethal concentrations of lead acetate on heme synthesis and immune function in red-tailed hawks. Arch. Environ. Contam. Toxicol. 21:1991;72-77.
43. Sherman A.R. Zinc; copper; and iron nutriture and immunity. J. Nutr. 122:1992;604-609.
44. Sprietsma J.E. Zinc-controlled Th1/Th2 switch significantly determine development of diseases. Med. Hypotheses. 49:1997;1-14.
45. Surcel H.M., Troye-Blomberg M., Paulie S., Andersson G., Moreno C., Pasvol G., Ivanyi J. Th1/Th2 profiles in tuberculosis; based on the proliferation and cytokine response of blood lymphocytes to mycobacterial antigens. Immunology. 81:1994;171-176.
46. Swain S.L., Bradley L.M., Croft M., Tonkonogy S., Atkins G., Weinberg A.D., Duncan D.D., Hedrick S.M., Dutton R.W., Huston G. Helper T cell subsets: phenotype; function and role of lymphokines in regulating their development. Immunol. Rev. 123:1991;115-144.
47. Talcott P.A., Koller L.D. The effect of inorganic lead and/or a polychlorinated biphenyl on the developing immune system of mice. J. Toxicol. Environ. Health. 12:1983;337-352.
48. U.S. Food and Drug Administration, 1991. Succimer approved for severe lead poisoning, FDA Med. Bull. March, 21, 5.
49. Waldorf H.A., Walsh L.J., Schecher N.M., Murphy G.F. Early cellular events in evolving cutaneous delayed hypersensitivity in humans. Am. J. Pathol. 138:1991;477-486.
50. Warner G.L., Lawrence D.A. The effect of metals on IL-2-related lymphocyte proliferation. Int. J. Immunopharmacol. 10:1988;629-637.
51. Wellinghausen N., Martin M., Rink L. Zinc inhibits interleukin-1-dependent T cell stimulation. Eur. J. Immunol. 27:1997;2529-2535.
52. Zelikoff J.T., Smialowicz R., Bigazzi P.E., Goyer R.A., Lawrence D.A., Maibach H.I., Gardner D. Immunomodulation by metals. Fundam. Appl. Toxicol. 22:1994;1-7.